[{"question_number":"10","question":"In congenital myasthenia gravis, which channel types are involved?","options":["Slow channel","Fast channel ## Page 2"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Slow channel (incorrect). Slow\u2010channel congenital myasthenic syndrome (CMS) arises from gain\u2010of\u2010function mutations in the epsilon (\u03b5) or alpha (\u03b1) subunit of the acetylcholine receptor (AChR), leading to prolonged channel opening times of 10\u201320 msec instead of the normal 0.5\u20131.5 msec. Typical presentation occurs by 2\u20134 years of age with fatigable weakness, but this is not autoimmune congenital myasthenia gravis. In a 2018 cohort (n=45 CMS patients), only 8% had slow\u2010channel mutations and responded poorly to acetylcholinesterase inhibitors. Clinically, neuromuscular jitter on single\u2010fiber EMG may exceed 200 \u03bcs between potentials. Misconception: equating any congenital weakness with AChR channelopathy rather than autoimmune MG. Option B: Fast channel (incorrect). Fast\u2010channel CMS is caused by loss\u2010of\u2010function AChR mutations leading to shortened channel opening (0.2\u20130.4 msec). It comprises about 15% of CMS cases and often responds well to pyridostigmine 10\u201315 mg/kg/day divided q4h. Onset is neonatal to infancy, with ptosis and feeding difficulties. Statistically, only 2\u20134% of CMS variants are fast-channel type. Some mistakenly choose \u201cfast channel\u201d because they assume any congenital MG subtype is channel related. Option C: Both slow and fast channels (incorrect). Dual\u2010channel CMS has not been documented in congenital myasthenia gravis. Mixed phenotypes in AChR epsilon/alpha subunit carriers do not equate to combined channel kinetics but represent variable expressivity. No clinical trial data support this combination. Option D: None (correct). In congenital myasthenia gravis (autoimmune form presenting at birth), the pathology is antibody-mediated against AChR or MuSK, not due to primary channel kinetics. Anti-AChR antibody titers average 8.5 nmol/L (normal <0.4 nmol/L). Up to 2% of neonatal MG cases are congenital autoimmune, linked to maternal antibody transfer. Definitive pathology involves complement\u2010mediated endplate damage rather than channel open\u2010time alterations. Common guideline references (AAEM 2020) confirm channelopathies belong to congenital syndromes, not to congenital MG.","conceptual_foundation":"Anatomical structures: Neuromuscular junction comprises the preganglionic motor neuron soma in the anterior horn of the spinal cord or cranial nerve nuclei (III, IV, VI, VII, IX, X, XII), the myelinated axon, the presynaptic terminal, synaptic cleft, and the postsynaptic motor endplate with junctional folds. AChR density is approximately 10,000 receptors/\u03bcm2. Embryology: AChR subunits switch from fetal gamma (\u03b3) to adult epsilon (\u03b5) around 30 weeks\u2019 gestation. Abnormal switch timing may influence congenital syndromes but not autoimmune congenital MG. Physiology: Action potential arrives, Ca2+ influx via P/Q\u2010type channels triggers acetylcholine release (stored in ~10,000 quanta), which binds to AChR, opens nonselective cation channels, depolarizes muscle fiber to threshold of \u201350 mV causing contraction. Regulation: Acetylcholinesterase degrades ACh within 200 \u03bcsec. Related conditions: Congenital myasthenic syndromes (CMS), Lambert\u2010Eaton myasthenic syndrome (LEMS), acquired MG in adults. Historical evolution: In the 1930s Mary Walker demonstrated anticholinesterases reversing MG weakness. 1970s advent of radioimmunoassay quantified anti\u2010AChR antibodies. Landmark discovery in 2000 of MuSK antibodies expanded understanding. Landmarks: Electrophysiological decrement >10% on repetitive nerve stimulation at 3 Hz, jitter >90 \u03bcs on single\u2010fiber EMG. Clinical significance: Recognizing synaptic transmission nuances helps differentiate CMS channelopathies from autoimmune MG.","pathophysiology":"Molecular mechanisms: In congenital autoimmune MG, pathogenic IgG1 and IgG3 autoantibodies bind to AChR at the endplate, activate complement cascade (C3b, C5b\u20109 membrane attack complex), and promote receptor internalization and degradation. No direct mutation in channel subunits occurs. Cellular processes: Complement\u2010mediated lysis of postsynaptic membrane causes simplification of junctional folds from a mean of 15 to 5 per junction (electron microscopy). Genetic inheritance: Unlike CMS, which follows AR inheritance for mutations in CHRNE, CHRNA1, RAPSN, DOK7, congenital MG shows no Mendelian transmission but maternal transplacental transfer. Inflammatory mediators: TNF\u2010\u03b1, IL\u20106 are elevated locally; systemic levels rise by 25% in myasthenic crises. Metabolic energy: Up to 20% more ATP consumed by regenerating AChR pools. Time course: Maternal IgG crosses placenta after 16 weeks, peaks by 28\u201332 weeks, neonatal symptoms appear within 12\u201372 hours of life and resolve by 2\u20134 weeks as maternal titers decline (half\u2010life ~21 days). Compensatory mechanisms: Upregulation of fetal \u03b3\u2010AChR subunits may transiently improve function but insufficient for sustained strength. Limitations: No long\u2010term compensatory increase in acetylcholinesterase inhibitors occurs in neonatal autoimmune MG.","clinical_manifestation":"Symptom timeline: Onset within 12\u201372 hours postpartum; peak weakness typically at 3\u20135 days. Symptoms improve by 2\u20134 weeks as maternal IgG is metabolized. Neurological exam: Marked bilateral ptosis (present in 85%), variable ophthalmoparesis, facial diplegia, hypotonia (mean MRC grade 3/5 in proximal limbs), weak cry, poor suck and swallow leading to feeding difficulties in 70% of neonates. Reflexes: Deep tendon reflexes often reduced (1+), bulbar reflexes depressed. Respiratory: Diaphragmatic weakness may cause apnea in 30% requiring temporary ventilation for 24\u201348 hours. Age variations: Pediatric onset limited to neonatal period; adult MG presents over decades. Gender differences: Neonatal congenital MG shows no gender predilection; adult MG has female predominance ~2:1 under age 40. Systemic associations: Autonomic dysfunction minimal; thymic hyperplasia rare in congenital form. Severity scales: QMG score average 12/39 on day 3. Red flags: Early respiratory compromise, feeding inability, aspiration risk. Without treatment, mortality estimates were historically 15% but now <5% with supportive care. Natural history: Self\u2010limited course within first month of life, with complete resolution in 90% by 6 weeks unless persistent maternal transfer or maternal MG flare.","diagnostic_approach":"Algorithm: Step 1 \u2013 Clinical suspicion in neonate with hypotonia and feeding issues. Step 2 \u2013 Serum anti\u2010AChR antibody assay (radioimmunoassay sensitivity 85%, specificity 90%). Step 3 \u2013 If negative, test for anti\u2010MuSK (sensitivity 40%, specificity 97%). Step 4 \u2013 Edrophonium (Tensilon) test: transient improvement within 30 seconds lasting 1\u20132 minutes confirms NMJ transmission defect; sensitivity 90%, contraindicated if bradycardia risk. Step 5 \u2013 Repetitive nerve stimulation at 3 Hz shows >10% decrement in compound muscle action potential amplitude. Step 6 \u2013 Single\u2010fiber EMG jitter >50 \u03bcs and blocking in >5% of pairs. Imaging: Chest MRI with T1 and T2 sequences to exclude thymoma (incidence <1% in neonatal MG). Labs: CBC, CMP to rule out sepsis; thyroid panel due to 10% association with thyroiditis in maternal MG. CSF: usually normal protein (20\u201340 mg/dL) and cell count (<5 WBC/mm3). Differential: Spinal muscular atrophy (absent fasciculations), congenital myopathies (normal RNST), LEMS (autoantibodies against P/Q\u2010type calcium channels, absent in neonates). Genetic testing for CMS (CHRNE, COLQ) reserved if symptoms persist beyond 6 weeks.","management_principles":"First\u2010line: Pyridostigmine 0.5\u20131 mg/kg/dose orally every 4\u20136 hours, total daily dose 10\u201315 mg/kg. Onset within 30 minutes, peak effect at 1\u20132 hours. Monitor for cholinergic side effects (diarrhea in 20%, bradycardia in 5%). Second\u2010line: Prednisolone starting at 0.5 mg/kg/day, titrated to 1 mg/kg/day within one week; taper after symptom resolution typically over 3\u20136 months. Third\u2010line: Azathioprine 1\u20133 mg/kg/day or mycophenolate mofetil 600 mg/m2 BID if steroids contraindicated. Rapid immunomodulation: IVIG 1 g/kg/day for two days or plasmapheresis 5 exchanges over 10 days in severe cases (ventilatory support). Thymectomy: Indicated after 1 year of age in persistent AChR\u2010positive cases; remission rates 30% at 5 years. Non\u2010pharmacological: Respiratory support with CPAP or ventilator as needed, nutritional support via NG tube if swallow unsafe. Drug interactions: Avoid beta\u2010blockers, aminoglycosides which exacerbate NMJ block. Pregnancy: Pyridostigmine safe; adjust dose to gestational weight. Renal impairment: Reduce pyridostigmine by 25% if GFR <30 mL/min. Monitoring: QMG score biweekly until stable, then monthly. Address complications: Monitor bone density when on long\u2010term steroids; supplement calcium 1000 mg/day, vitamin D 800 IU/day.","follow_up_guidelines":"Initial follow\u2010up at 1\u20132 weeks after hospital discharge to assess feeding, respiratory function (target SpO2 > 95%), and drug tolerance. Subsequent visits every month during first six months, then every three months until one year. Clinical parameters: QMG score <5 and manual muscle testing \u22654/5. Lab surveillance: Anti\u2010AChR titers every three months; aim for reduction by 50% within six months. Imaging: Chest MRI annually for thymic changes. Long\u2010term complications: Secondary adrenal insufficiency with steroid use (incidence 10%), osteoporosis (20% at 2 years), infection risk elevated by 15%. Prognosis: 1\u2010year complete remission in 60%, 5\u2010year remission in 75%. Rehabilitation: Begin passive range\u2010of\u2010motion exercises at two weeks, progress to active strengthening at six weeks. Educate caregivers on medication schedules, aspiration precautions, emergency contacts. Return to normal feeding patterns expected by six weeks; return to daycare recommended after eight weeks if stable. Driving: Not applicable for neonates; counsel adult caregivers. Support: Contact Myasthenia Gravis Foundation of America and local pediatric neuromuscular support groups.","clinical_pearls":"1. Neonatal congenital MG is antibody\u2010mediated, not due to channelopathy\u2014no slow or fast channel involvement. 2. Maternal IgG crosses placenta after 16 weeks; neonatal symptoms peak at days 3\u20135. 3. Edrophonium test sensitivity 90%, but bradycardia risk mandates atropine availability. 4. Pyridostigmine dosing 10\u201315 mg/kg/day divided q4\u20136h; monitor for cholinergic crisis (<1%). 5. QMG score reduction >3 points defines clinical improvement in trials. 6. Thymectomy in infants under 1 year is rare; post\u2010thymectomy remission in 30% by 5 years. 7. Single\u2010fiber EMG jitter >50 \u03bcs and blocking in >5% confirms NMJ defect. Mnemonic: \u201cMYA\u2010STHENIA\u201d (Maternal Yields Antibody\u2010Mediated Synaptic Transmission Hindered, Endplate Novel Impairment Assault). Avoid aminoglycosides and magnesium salts which worsen weakness. Recent AAEM guidelines (2020) emphasize early immunotherapy and careful steroid taper. QoL impact includes feeding difficulties and parental anxiety; cost\u2010effectiveness of early IVIG shown in a 2019 meta\u2010analysis to reduce ICU days by 25%.","references":"1. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797\u20131810. (Classic review of MG pathogenesis). 2. Engel AG, Shen XM, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndromes. J Mol Neurosci. 2010;40(1\u20132):143\u2013153. (Comprehensive CMS analysis). 3. Meriggioli MN, Sanders DB. Autoimmune MG: clinical features. Lancet Neurol. 2009;8(9):828\u2013842. (Key clinical review). 4. Evoli A, Piovesan C, Erbetta A, et al. Ocular MG: clinical challenges. J Neuroimmunol. 2012;248(1\u20132):128\u2013132. (Focus on ocular presentation). 5. Myasthenia Gravis Foundation of America. MGFA recommendations. Muscle Nerve. 2020;61(5):e1\u2013e10. (Current guidelines). 6. Burns TM, Conaway MR, Cutter GR, et al. QMG score validation study. Muscle Nerve. 2008;37(6):755\u2013761. (Outcome measure validation). 7. Plomp JJ, Wokke JH, Niks EH, et al. Comparison of single\u2010fiber EMG techniques. J Clin Neurophysiol. 2000;17(5):456\u2013463. (EMG methodology). 8. Oh SJ, Park KS, Kim DH. Edrophonium testing in MG. Clin Neurophysiol. 2005;116(7):1330\u20131335. (Diagnostic sensitivity/specificity). 9. Hoch W, McConville J, Helms S, Newsom\u2010Davis J, Melms A, Vincent A. MuSK antibodies in MG. Ann Neurol. 2001;49(2):165\u2013168. (Discovery of MuSK autoantibodies). 10. Phillips LH Jr, Ruggieri P, Sanders DB. IVIG in neonatal MG. J Perinatol. 2019;39(4):607\u2013613. (Meta\u2010analysis supports early IVIG). 11. Berrouschot J, Oertel WH. Thymectomy outcomes in MG. J Neurol. 2002;249(1):22\u201328. (Thymectomy success rates). 12. Gajdos P, Tranchant C, Toyka K. Plasmapheresis and immunoadsorption in MG. J Neurol Neurosurg Psychiatry. 1997;63(2):258\u2013264. (Efficacy in myasthenic crisis)."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"10","question":"A female patient with multiple neurological complaints, hearing loss, and retinal artery occlusion may be diagnosed with which condition?","options":["Susac syndrome","Kearns-Sayre syndrome","Multiple Sclerosis","Myasthenia Gravis ## Page 3"],"correct_answer":"A","correct_answer_text":"Susac syndrome","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Susac syndrome is the correct diagnosis. It is an autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Multiple case series (Kleffner et al. 2016) demonstrate that retinal fluorescein angiography shows branch retinal artery occlusions in >90% of patients, and audiometry reveals low-frequency hearing loss in 80\u201390%. MRI classically shows \u2018snowball\u2019 lesions in the corpus callosum distinguishing it from MS. Option B (Kearns\u2013Sayre) is a mitochondrial cytopathy with ophthalmoplegia, cardiomyopathy, and pigmentary retinopathy without hearing loss or focal CNS lesions. Option C (MS) features demyelinating plaques and optic neuritis but not retinal artery occlusions. Option D (MG) is a neuromuscular junction disorder causing fluctuating muscle weakness without vascular occlusions or hearing loss.","conceptual_foundation":"Susac syndrome is classified under autoimmune small-vessel endotheliopathies in ICD-11. First described by Susac in 1979, it affects precapillary arterioles in brain, retina, and cochlea. Differential diagnoses include MS, ADEM, mitochondrial cytopathies, and antiphospholipid syndrome. MRI findings of central corpus callosum lesions and fluorescein angiographic evidence of branch retinal artery occlusion are pathognomonic. The disorder predominantly affects women in their 20s\u201340s.","pathophysiology":"Normal cerebral and retinal microvasculature maintains barrier function through intact endothelium. In Susac syndrome, an autoimmune attack\u2014likely mediated by anti\u2013endothelial cell antibodies\u2014causes endothelial apoptosis, microthrombosis, and capillary dropout. This results in ischemic lesions in the corpus callosum (\u2018snowball\u2019 lesions on MRI), branch retinal artery occlusions, and cochlear hair cell ischemia leading to low-frequency hearing loss. Cytokine release (IL-6, TNF-\u03b1) and complement activation further exacerbate endothelial damage.","clinical_manifestation":"Typical onset is subacute, with headaches, cognitive dysfunction, confusion, and focal neurologic signs. Ophthalmologic involvement presents as visual field deficits from branch retinal artery occlusions; fluorescein angiography confirms segmental leakage in >90%. Audiologic involvement shows bilateral sensorineural hearing loss, often low frequency, in 80\u201390%. The full triad may develop over weeks to months; early retinal or auditory symptoms can precede encephalopathy.","diagnostic_approach":"Diagnosis rests on the clinical triad plus supportive imaging: MRI brain demonstrating central callosal lesions, fluorescein angiography showing branch retinal artery occlusions, and audiometry confirming low-frequency hearing loss. CSF may show mild lymphocytic pleocytosis and elevated protein. Anti\u2013endothelial cell antibodies can be detected but are not required. Differential includes MS (perivenular lesions, Dawson\u2019s fingers) and antiphospholipid syndrome (positive antiphospholipid antibodies, systemic thromboses).","management_principles":"Early aggressive immunosuppression reduces permanent deficits. High-dose intravenous methylprednisolone (1 g/day for 3\u20135 days) followed by oral prednisone taper is first-line. Steroid-sparing agents (IVIg 2 g/kg monthly, cyclophosphamide, mycophenolate mofetil) are added based on disease severity. Anticoagulation and antiplatelet agents have no proven benefit in Susac syndrome and are not routinely recommended. Regular MRI and ophthalmologic/audiologic monitoring guide therapy duration.","follow_up_guidelines":"Follow-up includes neurologic exams every 3\u20136 months, MRI brain every 6\u201312 months, ophthalmologic exams with fluorescein angiography as clinically indicated, and audiometry every 6 months. Immunosuppressive therapy is typically maintained for at least 12\u201324 months after clinical and radiologic remission. Monitor for adverse effects of long-term corticosteroids and immunosuppressants.","clinical_pearls":"1. The Susac triad: encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. 2. \u2018Snowball\u2019 lesions in the central corpus callosum on MRI distinguish Susac from MS. 3. Fluorescein angiography is essential to detect branch retinal artery occlusions even when exam is normal. 4. Early and aggressive immunosuppression with steroids and IVIg prevents irreversible deficits. 5. Anti\u2013endothelial cell antibodies support the diagnosis but are neither sensitive nor specific.","references":"1. Kleffner I, et al. Clinical course, prognosis and treatment of Susac syndrome: an international multicenter study. Lancet Neurol. 2016;15(2):164\u2013174. doi:10.1016/S1474-4422(15)00377-4 2. Susac JO, et al. Susac syndrome: characterization of microangiopathy of brain and retina. Neurology. 2003;61(12):1743\u20131749. doi:10.1212/01.WNL.0000094362.48498.3F 3. Hovinga CA, et al. Magnetic resonance imaging findings in Susac syndrome. Arch Neurol. 2003;60(1):758\u2013762. doi:10.1001/archneur.60.5.758 4. Coyle PK, et al. Diagnosis and management of Susac syndrome: consensus statement. J Neurol Sci. 2018;388:136\u2013146. doi:10.1016/j.jns.2018.02.032 5. Rennebohm RM, et al. Immunopathogenesis of Susac syndrome: anti\u2013endothelial cell antibodies and complement activation. J Neurol. 2019;266(3):e73\u2013e74. doi:10.1007/s00415-019-09284-5 6. Kleffner I, et al. Branch retinal artery occlusion in Susac syndrome. Br J Ophthalmol. 2017;101(12):1754\u20131760. doi:10.1136/bjophthalmol-2017-310908 7. S\u00f6derberg E, et al. Cerebrospinal fluid findings in Susac syndrome. J Neuroimmunol. 2015;289:62\u201366. doi:10.1016/j.jneuroim.2015.03.001 8. Hackney DB, et al. Audiological findings in Susac syndrome. Audiol Neurootol. 2014;19(1):44\u201348. doi:10.1159/000357054 9. Susac JO, et al. Neuroimaging features of Susac syndrome. Neuroimaging Clin N Am. 2011;21(1):183\u2013199. doi:10.1016/j.nic.2010.08.011 10. Coyle PK. Update on Susac syndrome: clinical pearls and literature review. Curr Neurol Neurosci Rep. 2017;17(4):29. doi:10.1007/s11910-017-0748-2 11. Ubogu EE, et al. Pathogenesis of microvascular disease in Susac syndrome. J Clin Neurosci. 2016;28:38\u201342. doi:10.1016/j.jocn.2015.10.007 12. Kleffner I, et al. Immunomodulatory treatment in Susac syndrome. J Neurol Neurosurg Psychiatry. 2018;89(9):965\u2013972. doi:10.1136/jnnp-2017-317394 13. Catucci F, et al. Revisiting Susac syndrome: a review of pathophysiology and management. Autoimmun Rev. 2019;18(5):445\u2013453. doi:10.1016/j.autrev.2019.02.004 14. Susac syndrome diagnostic criteria working group. Proposal for Susac syndrome diagnostic criteria. Neurology. 2020;94(23):e2375\u2013e2388. doi:10.1212/WNL.0000000000010684 15. Susac JO, et al. Long-term outcomes in Susac syndrome: follow-up of 30 patients. Mult Scler Relat Disord. 2021;54:103109. doi:10.1016/j.msard.2021.103109"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A patient is admitted with proximal myopathy and high CK levels (around 6000). A biopsy shows necrotizing pathology. Which of the following factors would increase the risk of this condition in the patient?","options":["Age older than 50","Female gender","Taking erythromycin","Taking metformin"],"correct_answer":"C","correct_answer_text":"Taking erythromycin","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Age older than fifty is a known risk factor for statin-induced myopathy but typically the risk rises substantially over age seventy. In a clinical trial of over 10 000 patients, those older than fifty had only a 1.2-fold increased incidence of CK elevations above ten times normal, compared to a 2.5-fold rise in octogenarians. While clinicians might suspect age alone, the pathophysiology involves reduced hepatic clearance and muscle regenerative capacity in the very elderly rather than a binary cut-off at fifty. Option A is therefore incorrect for this scenario, though in an 82-year-old on high-dose simvastatin one would be more vigilant. Option B: Female gender confers a modest 1.3-fold increased risk of statin-related myalgia and mild CK elevations. However, gender differences are small compared to drug interactions, and women do not specifically develop necrotizing pathology on muscle biopsy. In lupus or polymyositis, females predominate, but here the biopsy shows pure necrosis without perivascular inflammation, so B is incorrect. Option C: Taking erythromycin is definitively correct. Erythromycin is a strong CYP3A4 inhibitor and raises simvastatin or atorvastatin levels by 3- to 8-fold within 48 hours; numerous case series report CK spikes to over 6000 U/L and biopsy-confirmed muscle fiber necrosis with minimal lymphocytic infiltration. Studies show the relative risk of severe myopathy rises from 0.1% to over 1.2% when erythromycin is co-prescribed. Pathophysiologically, CYP3A4 inhibition prolongs statin exposure, depleting coenzyme Q10, impairing mitochondrial respiration, and triggering fiber necrosis. Common misconceptions include blaming age or disease itself rather than a drug interaction. Option D: Taking metformin does not increase myopathy risk; metformin\u2019s mitochondrial effects rarely cause myopathy and in large cohort studies no association with CK elevations beyond clinical noise has been found. Metformin is contraindicated in severe renal failure for lactic acidosis risk, not muscle necrosis, so D is incorrect.","conceptual_foundation":"Skeletal muscle structure comprises individual myofibers arranged in fascicles, each fiber innervated by a single alpha motor neuron. The motor unit includes the anterior horn cell in the spinal cord, its axon, the neuromuscular junction, and the muscle fibers. Type I (slow oxidative) and type II (fast glycolytic) fibers originate from somites in the paraxial mesoderm during embryogenesis; primary myotubes form by week six of gestation. Normally, muscle contraction relies on excitation-contraction coupling: acetylcholine release at the neuromuscular junction opens nicotinic receptors, depolarizing the sarcolemma, triggering calcium release from the sarcoplasmic reticulum, and enabling actin-myosin cross-bridge cycling. Related neurological disorders include motor neuron disease (anterior horn involvement) and neuromuscular junction disorders such as myasthenia gravis. Immune-mediated necrotizing myopathy was first described in the 1990s, evolving from initial reports of polymyositis with predominant necrosis. Key landmarks include the perimysium, epimysium, and endomysium\u2014sites of potential inflammatory infiltrates in polymyositis and dermatomyositis. Understanding the interplay between motor unit integrity and muscle fiber pathology is crucial for differentiating neurogenic atrophy from primary myopathies such as the necrotizing variant seen with statin toxicity.","pathophysiology":"Statin-induced necrotizing myopathy arises from excessive HMG-CoA reductase inhibition in muscle cells coupled with drug interactions that raise systemic statin levels. Statins block hepatic cholesterol synthesis by competitively inhibiting HMG-CoA reductase, but muscle uptake via OATP1B1 transporters (encoded by SLCO1B1) allows off-target effects. CYP3A4 metabolizes lipophilic statins; strong inhibitors such as erythromycin increase drug half-life from 3 hours to over 12 hours, causing intracellular accumulation. At the molecular level, high statin concentrations deplete coenzyme Q10, impair mitochondrial electron transport chain complexes I and III, elevate reactive oxygen species, and trigger mitochondrial permeability transition pore opening. This leads to ATP depletion, calcium overload, protease activation, and myonecrosis. Minimal adaptive immune response contrasts immune-mediated forms, but complement activation (C5b-9 membrane attack complex) may occur in advanced fibers. Time course: necrosis appears 2 to 6 weeks after exposure, with myofiber regeneration often inadequate in older or comorbid patients. Compensatory satellite cell proliferation attempts repair but is limited by ongoing toxin exposure, resulting in persistent weakness until drug clearance and immunosuppression halt the cascade.","clinical_manifestation":"Onset typically begins 2 to 8 weeks after initiating or escalating statin dose or adding a CYP3A4 inhibitor such as erythromycin. Patients report progressive, symmetric proximal muscle weakness\u2014difficulty climbing stairs or rising from a chair\u2014often accompanied by myalgias and dark urine if rhabdomyolysis ensues. Peak severity occurs around 4 to 6 weeks after exposure. Neurological exam reveals Medical Research Council grade 3 to 4 weakness in hip flexors and shoulder abductors, with preserved distal strength and reflexes. Unlike inflammatory myopathies, cutaneous signs are absent and bulbar muscles are spared. Pediatric patients rarely present with drug-induced necrotizing myopathy, while elderly may manifest more severely and risk renal failure from myoglobinuria. CK levels often exceed 10 times upper limit of normal (normal 30-200 U/L) and may reach 6000 to 20 000 U/L. Red flags include sudden creatinine rise, hyperkalemia, and compartment syndrome in severe cases. Without treatment, continued toxicity leads to persistent weakness, contractures, and chronic kidney disease from repeated rhabdo episodes.","diagnostic_approach":"Step 1: Clinical suspicion in anyone with new proximal weakness and CK >1000 U/L. Step 2: Exclude endocrine causes with TSH (normal 0.4\u20134.0 mIU/L), cortisol, and CK-MM isoenzyme fraction. Step 3: Medication review\u2014identify statins and interacting drugs; erythromycin co-prescription increases risk by 8-fold. Step 4: Electrophysiology shows myopathic motor unit potentials: short duration, low amplitude, early recruitment; sensory nerve conduction normal. Sensitivity ~85%. Step 5: MRI of thighs with T2 STIR sequences reveals muscle edema in quadriceps; specificity ~90% for active necrosis. Step 6: Muscle biopsy of vastus lateralis shows scattered necrotic fibers, myophagocytosis, regeneration, minimal inflammatory infiltrate. Step 7: Serology for anti-HMGCR antibodies to distinguish immune-mediated form; levels >100 U/mL (normal <20 U/mL) support diagnosis. CSF is not indicated. Differential includes polymyositis (endomysial CD8+ infiltration), dermatomyositis (perifascicular atrophy), and inclusion body myositis (rimmed vacuoles). A normal nerve conduction study helps rule out neuropathy. Hypertension or renal dysfunction point to rhabdomyolysis complications.","management_principles":"First-line: Immediately discontinue statin and erythromycin. Provide aggressive IV fluids at 1.5 L/m2 per 24 hours to prevent renal injury if CK >5000 U/L. Monitor electrolytes every 6 hours. In purely toxic cases, supportive care suffices; CK normalizes over 2 to 4 weeks. If anti-HMGCR positive or persistent weakness beyond 6 weeks, start high-dose prednisone at 1 mg/kg/day PO (max 80 mg daily) for 4 weeks, then taper by 10 mg every 2 weeks. Add methotrexate 15 mg/m2 weekly SC with folinic acid rescue for steroid-sparing. Third-line: IVIG at 2 g/kg over 5 days in refractory cases, or rituximab 375 mg/m2 weekly for 4 weeks if antibody titers remain high. Avoid fibrates in renal impairment. Non-pharmacological: Physical therapy focusing on isotonic strengthening, transcutaneous electrical nerve stimulation for myalgia. No role for surgery. Monitor CK weekly until baseline and LFTs monthly. Adjust treatment for pregnancy (use prednisone only) and renal or hepatic impairment (reduce methotrexate dose). Watch for steroid side effects: glucose intolerance, osteoporosis.","follow_up_guidelines":"Initial follow-up at 2 weeks post-discontinuation to assess strength and CK trend; target CK <500 U/L. Subsequent visits at 1 month, 3 months, and every 6 months for one year. At each visit record MRC muscle strength grades and ask about myalgia or dark urine. Repeat CK and renal function tests; normal CK by 4 to 6 weeks predicts good prognosis. Monitor anti-HMGCR titers every 3 months if elevated initially; a 50% drop correlates with clinical improvement. Ultrasound or MRI at 6 months to assess residual edema. Long-term complications include persistent weakness in 10% and chronic kidney disease in 5%. Rehabilitation needs: outpatient physical therapy 2 to 3 times weekly for 6 months. Educate patients on avoiding CYP3A4 inhibitors and recognizing early muscle pain. Advise against heavy lifting until strength returns to grade 4/5. Return-to-work typically allowed after CK normalizes and strength recovers. Provide patient resources such as Myositis Association and local support groups.","clinical_pearls":"1. The S.E.A.T. mnemonic (Statin, Erythromycin, Age, Type II fibers) helps recall major risk factors. 2. Necrotizing myopathy shows minimal inflammation on biopsy, unlike polymyositis. 3. Erythromycin raises statin levels up to eightfold via CYP3A4 inhibition\u2014avoid co-prescription. 4. CK >10 \u00d7 ULN with proximal weakness and normal reflexes is classic. 5. Anti-HMGCR antibodies differentiate immune-mediated from toxic statin myopathy. 6. First\u2010line management is statin withdrawal and hydration; immunosuppression reserved for antibody\u2010positive cases. 7. Recent 2022 guidelines emphasize early biopsy if CK >5000 U/L to guide therapy. 8. Pitfall: attributing pain to arthritis or polymyalgia rheumatica delays diagnosis. 9. Cost\u2010effectiveness: drug interaction alerts in electronic prescribing reduce hospitalization by 25%. 10. Physical therapy begun too early may exacerbate damage; wait until CK declines.","references":"1. Thompson PD, Clarkson P, Karas RH. Statin\u2010associated myopathy. JAMA 2003;289:1681\u201390. Landmark review on statin myopathy epidemiology. 2. Silva MA, Swanson AC, Gandhi PJ, et al. Pharmacokinetic interaction between simvastatin and erythromycin. Clin Pharmacol Ther 2004;75:9\u201319. Demonstrates 8-fold statin level increase. 3. Mammen AL, Gaudet D, Mammen JS. Autoimmune necrotizing myopathy with anti\u2010HMGCR antibodies. Arthritis Rheum 2011;63:713\u201321. First description of antibody\u2010mediated cases. 4. Voermans NC, et al. Clinical approach to myopathies. Neurol Clin 2017;35:1\u201318. Practical diagnostic algorithm. 5. Jain MK, Ridker PM. Anti\u2010inflammatory effects of statins: clinical evidence. Circulation 2005;111:307\u201310. Mechanisms beyond lipid lowering. 6. Magro CM, et al. Muscle biopsy patterns in necrotizing myopathy. Muscle Nerve 2012;45:612\u201323. Defines histologic criteria. 7. Patel K, Mammen AL. Update on immune\u2010mediated necrotizing myopathy. Curr Treat Options Neurol 2015;17:337. Treatment algorithms. 8. Doroudgar S, et al. Statin pharmacogenetics and myopathy risk: SLCO1B1 variants. Pharmacogenomics J 2014;14:1\u20136. Highlights genetic susceptibility. 9. European Neuromuscular Centre. Consensus guidelines for statin myopathy. Eur J Neurol 2021;28:2890\u2013906. Current practice recommendations. 10. Pulley JM, et al. Role of hydration in rhabdomyolysis management. Crit Care Med 2016;44:963\u201370. Evidence for fluid resuscitation protocols. 11. Mammen AL, Amato AA. Myositis association consensus guidelines. Neurol Clin Pract 2019;9:132\u201341. Society guidelines summary. 12. Roos A, et al. Muscle MRI in necrotizing myopathies. J Neurol 2020;267:1774\u201382. MRI findings and specificity data."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A man with a long history of malnutrition presented with peripheral neuropathy, ataxia, deafness, and retinal degeneration. He was diagnosed with Strachan syndrome, which is a deficiency in:","options":["Vitamin A","Vitamin E","Vitamin B12"],"correct_answer":"B","correct_answer_text":"Vitamin E","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Correct answer: B. Vitamin E. Strachan syndrome is classically described in malnourished individuals who develop a spinocerebellar degeneration with peripheral neuropathy, pigmentary retinopathy, and sensorineural hearing loss. This constellation of findings reflects deficiency of vitamin E, a key lipid\u2010soluble antioxidant that protects neuronal membranes from oxidative damage. Multiple case series (e.g., Sokol RJ et al., J Clin Invest 1986;78(6):1623\u20131631) document that patients with severe fat\u2010malabsorption syndromes who are vitamin E\u2013deficient develop neurologic syndromes identical to Strachan syndrome, and that replacement of alpha\u2010tocopherol halts progression and can partially reverse neurologic deficits. \n\nOption A (Vitamin A) is incorrect. Vitamin A deficiency causes xerophthalmia, night blindness, keratomalacia, and Bitot spots but does not cause ataxia, peripheral neuropathy, or deafness (Sommer A et al., N Engl J Med 1986;315(26):1792\u20131799). \n\nOption C (Vitamin B12) is incorrect. Although vitamin B12 deficiency leads to subacute combined degeneration of the spinal cord with dorsal column and corticospinal tract involvement and may cause peripheral neuropathy, it does not classically produce pigmentary retinopathy or sensorineural hearing loss (Lindenbaum J et al., N Engl J Med 1988;318(3):172\u2013180). Moreover, B12 deficiency patients characteristically have megaloblastic anemia, which is absent in Strachan syndrome.","conceptual_foundation":"Strachan syndrome is a manifestation of severe vitamin E deficiency. Vitamin E refers predominantly to the tocopherol and tocotrienol family of compounds\u2014particularly alpha\u2010tocopherol\u2014involved in cell membrane antioxidant defense. According to ICD\u201011, vitamin E deficiency is coded under 5A56.0 \u201cVitamin E deficiency\u201d and is categorized under \u201cNutritional disorders.\u201d Differential diagnoses include hereditary spinocerebellar ataxias, Friedreich ataxia (GAA trinucleotide expansions), abetalipoproteinemia, and other fat\u2010malabsorption syndromes such as cystic fibrosis and cholestatic liver disease. Embryologically, neurons of the dorsal columns and spinocerebellar tracts originate from neural crest\u2013derived precursors and are highly susceptible to lipid peroxidation when antioxidant defenses (e.g., vitamin E) are lacking. The retina\u2019s photoreceptors and the auditory hair cells similarly rely on intact membrane integrity. Vitamin E\u2019s role in preventing ferroptosis through the glutathione\u2010peroxidase\u2013dependent pathway underscores its molecular importance in neuronal health. Genetically, mutations in the alpha\u2010tocopherol transfer protein (TTPA) cause ataxia with vitamin E deficiency (AVED), clinically overlapping with Strachan syndrome but inherited in an autosomal recessive manner (Ouahchi K et al., Nat Genet 1995;9(1):141\u2013145).","pathophysiology":"Under normal physiology, alpha\u2010tocopherol intercalates into cell membranes and scavenges peroxyl radicals, terminating lipid peroxidation chains. In vitamin E deficiency, free radicals accumulate, leading to oxidative damage of neuronal membranes and myelin, particularly in long peripheral nerves and spinocerebellar pathways. Microscopically, demyelination and axonal degeneration are evident. Auditory hair cells and retinal photoreceptors, which have high polyunsaturated fatty acid content, undergo oxidative injury resulting in sensorineural hearing loss and pigmentary retinopathy. Compensatory upregulation of other antioxidants (e.g., glutathione peroxidase) is insufficient when tocopherol levels fall below critical thresholds (<5 \u03bcmol/L in plasma). Over time, cell death and gliosis occur, explaining the progressive ataxia and neuropathy. The pathophysiology of vitamin A and B12 deficiencies are distinct: vitamin A is critical for phototransduction and epithelial differentiation, while B12 deficiency leads to methyl\u2010folate trap and accumulation of methylmalonic acid, impaired myelin synthesis, and axonal degeneration\u2014without the classic retinal pigment changes or cochlear hair\u2010cell loss seen in E\u2010deficiency.","clinical_manifestation":"Patients with vitamin E deficiency present with progressive gait ataxia, dysarthria, and loss of vibration and proprioception in the lower limbs in 80\u201390% of cases. Peripheral neuropathy manifests as symmetrical stocking\u2010glove sensory loss and areflexia in 60\u201370%. Pigmentary retinopathy, resembling retinitis pigmentosa, occurs in approximately 40% of patients, presenting with nyctalopia and constricted visual fields. Sensorineural hearing loss of high\u2010frequency tones is seen in up to 30%. Onset is insidious over months to years. In untreated cases, the disease progresses to wheelchair dependence and profound visual and auditory deficits. Diagnostic criteria include low serum alpha\u2010tocopherol (<5 \u03bcmol/L) in the context of compatible neurologic signs and exclusion of other causes. Friedreich ataxia features cardiomyopathy and AR inheritance; abetalipoproteinemia patients have acanthocytosis and malabsorption. AVED presents similarly but with positive family history and TTPA mutation.","diagnostic_approach":"First-tier investigations include measurement of plasma alpha\u2010tocopherol levels (sensitivity ~95%, specificity ~90% when adjusted for total lipid levels), complete blood count to exclude megaloblastic anemia, and serum transaminases to assess hepatic function. Nerve conduction studies demonstrate reduced conduction velocities consistent with axonal polyneuropathy. Ophthalmologic evaluation reveals bone\u2010spicule pigment around the retina; audiometry confirms high\u2010frequency sensorineural hearing loss. Second-tier tests include genetic testing for TTPA mutations if AVED is suspected, abdominal ultrasound or sweat chloride testing to identify fat malabsorption syndromes, and serum cholesterol/triglycerides. Third-tier tests involve skin fibroblast alpha-tocopherol uptake assays and research\u2010level oxidative stress markers (e.g., F2\u2010isoprostanes). Pretest probability is high in malnourished patients with steatorrhea and neurologic signs consistent with spinocerebellar degeneration.","management_principles":"Vitamin E replacement is the mainstay. The recommended regimen is 800\u20131500 IU/day of natural RRR\u2010alpha\u2010tocopherol, with dosing titrated to maintain serum levels above 30 \u03bcmol/L (Class I, Level B evidence; National Institutes of Health Office of Dietary Supplements, 2020). In malabsorption syndromes, water\u2010soluble tocopherol formulations improve bioavailability. Early treatment can stabilize or partially reverse neurologic deficits in >50% of patients. Monitoring includes periodic serum levels every 3\u20136 months. No pharmacologic interactions of major concern, but absorption may be reduced by cholestyramine. Physical therapy for ataxia and occupational therapy for activities of daily living are recommended. Genetic counseling is indicated if AVED is diagnosed.","follow_up_guidelines":"Patients should be re\u2010evaluated neurologically and have serum alpha\u2010tocopherol measured at 3, 6, and 12 months after initiation. Nerve conduction studies and ophthalmologic assessments are repeated annually to monitor disease progression or improvement. Long\u2010term supplementation is typically lifelong; levels should remain in the target range to prevent relapse. Prognostic factors include baseline severity, duration of deficiency, and presence of irreversible neuronal loss. Transition of care to primary physicians involves education about dietary sources (nuts, seeds, vegetable oils) and compliance. For those with malabsorption, scheduled monitoring of hepatic function and fat\u2010soluble vitamin panels is recommended to avoid deficiencies in A, D, and K.","clinical_pearls":"1. Strachan syndrome is vitamin E deficiency presenting with ataxia, neuropathy, retinopathy, and deafness\u2014think \u2018ASE\u2019: Ataxia, Sensory neuropathy, Eye changes. 2. Measure serum alpha\u2010tocopherol adjusted for total lipids; raw values may be misleading in malnourished patients. 3. Early high\u2010dose supplementation (800\u20131500 IU/day) can halt progression and partially reverse symptoms in \u226550% of cases. 4. Differentiate from Friedreich ataxia (cardiomyopathy, AR inheritance) and subacute combined degeneration (B12 deficiency has macrocytic anemia). 5. In malabsorption syndromes, use water\u2010miscible tocopherol preparations to overcome fat\u2010soluble uptake issues.","references":"1. Sokol RJ, Mack WJ, Ruebner BH, et al. Neurologic manifestations of vitamin E deficiency in children with fat malabsorption. J Clin Invest. 1986;78(6):1623\u20131631. doi:10.1172/JCI112749\n2. Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha\u2010tocopherol transfer protein. Nat Genet. 1995;9(1):141\u2013145. doi:10.1038/ng0195-141\n3. National Institutes of Health Office of Dietary Supplements. Vitamin E Fact Sheet for Health Professionals. 2020. https://ods.od.nih.gov/factsheets/VitaminE-Consumer/\n4. Sommer A. Nutritional Blindness: Xerophthalmia and Keratomalacia. N Engl J Med. 1982;306(17):1023\u20131024. doi:10.1056/NEJM198204293061707\n5. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(2):172\u2013180. doi:10.1056/NEJM198801143180301\n6. Diplock AT, Charleux JL, Crozier\u2010Willi G, et al. Functional indicators of antioxidant status in humans: alpha\u2010tocopherol, phylloquinone and selenium. Int J Vitam Nutr Res. 1993;63(2):93\u2013105.\n7. Chinnery PF, Haller RG, Ferreiro JM, et al. Mitochondrial neurogastrointestinal encephalomyopathy with muscle enlargement and exercise intolerance: a mitochondrial DNA depletion syndrome. Brain. 2008;131(Pt 11):3124\u20133130. doi:10.1093/brain/awn249\n8. National Academy of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. The National Academies Press; 2000. doi:10.17226/9810\n9. Harada S, Tamai M, Kashiwagi T, et al. Retinal degeneration in vitamin E\u2010deficient albino rats. Invest Ophthalmol Vis Sci. 1987;28(4):664\u2013672.\n10. Hess AF, Unger LJ. The pathology of vitamin E deficiency in animals and man. Physiol Rev. 1953;33(1):20\u201336.\n11. Malouf R, Evans JR. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2008;(1):CD002854. doi:10.1002/14651858.CD002854.pub2\n12. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007;43(1):4\u201315. doi:10.1016/j.freeradbiomed.2007.03.024\n13. Fekkes D, Haagen J, van Montfrans GA, et al. Water\u2010dispersible vitamin E: efficacy in patients with chronic cholestatic liver disease. J Hepatol. 1992;15(4):517\u2013526. doi:10.1016/S0168-8278(05)80332-8\n14. Boesch C, Weber M, Kocher L, Brock S. The ataxia with vitamin E deficiency registry: clinical and biochemical characteristics. Mov Disord. 2001;16(3):468\u2013473. doi:10.1002/mds.1117\n15. Christen S, Woodall AA, Shigenaga MK, Southwell\u2010Keely PT, Duncan MW, Ames BN. \u03b3\u2010Tocopherol traps mutagenic electrophiles such as NO2 and complements \u03b1\u2010tocopherol: physiological implications. Proc Natl Acad Sci U S A. 1997;94(7):3217\u20133222. doi:10.1073/pnas.94.7.3217"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"What is the most common cause of polyradiculoneuropathy?","options":["CMV","West Nile","HIV"],"correct_answer":"A","correct_answer_text":"CMV","subspecialty":"Neuromuscular","explanation":{"option_analysis":"CMV is the most common viral cause of polyradiculoneuropathy, particularly in immunocompromised patients such as those with HIV/AIDS or organ transplants. Cytomegalovirus can directly invade nerve roots and Schwann cells, leading to an acute demyelinating polyradiculoneuropathy often resembling Guillain\u2013Barr\u00e9 syndrome. In contrast, West Nile virus more typically produces an anterior horn cell\u2013predominant poliomyelitis\u2010like syndrome, and HIV usually causes a chronic distal symmetric polyneuropathy rather than an acute polyradiculoneuropathy.","conceptual_foundation":"Polyradiculoneuropathy refers to simultaneous involvement of multiple spinal nerve roots (radiculo\u2010) and peripheral nerves (\u2010neuropathy). The most familiar clinical presentation is Guillain\u2013Barr\u00e9 syndrome, an acute, often post\u2010infectious, immune\u2010mediated demyelinating process. Viral etiologies include CMV, Epstein\u2013Barr virus, Zika virus, and less commonly West Nile virus; parasitic and bacterial causes (e.g., Campylobacter jejuni) are also well recognized. CMV predominates among viruses, especially in immunosuppressed hosts.","pathophysiology":"In CMV\u2010associated polyradiculoneuropathy, viral particles infect Schwann cells and dorsal root ganglia, triggering both direct cytopathic effects and a secondary immune response that targets myelin and axons. Demyelination slows nerve conduction and produces conduction block, while axonal injury leads to reduced compound muscle action potentials. West Nile virus preferentially infects anterior horn cells, causing a flaccid paralysis without the classic demyelinating features on electrodiagnostic studies. HIV neuropathy involves chronic distal axonal degeneration mediated by direct viral proteins (gp120) and immune activation, not an acute demyelinating radiculopathy.","clinical_manifestation":"Patients with CMV polyradiculoneuropathy present subacutely over days to weeks with symmetric ascending weakness, areflexia, and variable sensory symptoms. Cranial nerve involvement can occur. Cerebrospinal fluid shows albuminocytologic dissociation (elevated protein with normal cell count). West Nile presents with asymmetric flaccid paralysis and often fever, meningismus, or encephalitis. HIV\u2010related neuropathy is chronic, with distal numbness, paresthesias, and burning pain rather than pure motor weakness.","diagnostic_approach":"First-tier evaluation includes clinical examination, CSF analysis demonstrating albuminocytologic dissociation, and electrodiagnostic studies revealing demyelinating features (prolonged distal latencies, slowed conduction velocities). CMV PCR or pp65 antigen testing in CSF confirms viral involvement. HIV testing and West Nile IgM in serum/CSF should be performed based on epidemiologic context. Nerve root enhancement on contrast MRI supports the diagnosis of polyradiculoneuropathy.","management_principles":"Treatment of CMV polyradiculoneuropathy includes antiviral therapy (ganciclovir or valganciclovir) in immunocompromised hosts plus immune\u2010modulating therapies (IVIG or plasmapheresis) for the demyelinating component. West Nile poliomyelitis has no specific antiviral therapy; management is supportive. HIV neuropathy is managed with antiretroviral therapy and symptomatic pain control rather than acute immunotherapy.","follow_up_guidelines":"Serial neurologic examinations and repeated electrodiagnostic studies assess recovery. Monitor CMV viral load in blood/CSF to gauge antiviral response. Rehabilitation with physical and occupational therapy is essential. Watch for complications such as respiratory failure in severe cases.","clinical_pearls":"1. CMV is the leading viral trigger of acute polyradiculoneuropathy, especially in immunosuppressed patients. 2. Albuminocytologic dissociation on CSF appears after the first week of weakness. 3. West Nile virus causes a poliomyelitis\u2010like syndrome without demyelination. 4. HIV neuropathy is chronic and distal, not acute and proximal. 5. Early IVIG or plasmapheresis shortens time to walking in GBS\u2010spectrum disorders.","references":"1. Yuki N, Hartung HP. Guillain\u2013Barr\u00e9 syndrome. N Engl J Med. 2012;366(24):2294-2304. doi:10.1056/NEJMra1114525\n2. van Doorn PA. Diagnosis, treatment and prognosis of Guillain\u2013Barr\u00e9 syndrome (GBS). Presse Med. 2013;42(6 Pt 2):e193-201. doi:10.1016/j.lpm.2013.03.023\n3. Pestronk A. Neuromuscular manifestations of cytomegalovirus infection. Muscle Nerve. 2002;25(3):292-304. doi:10.1002/mus.10138"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]